REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

TaiRx, Inc. (Taiwan, China)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: TaiRx, Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

TaiRx, Inc. is mainly engaged in medical pharmacy. The company's pharmaceutical products include anti-cancer, sepsis and so on. TaiRx was established in 2011 and located in Taipei City.

Headquarters
6F-1, No. 66, San-Chung Road, Nankang Business Park
Taipei City; Taipei City;

Contact Details: Purchase the TaiRx, Inc. report to view the information.

Website: http://www.trx.com.tw

Basic Information
Total Employees:
Purchase the TaiRx, Inc. report to view the information.
Outstanding Shares:
Purchase the TaiRx, Inc. report to view the information.
Financial Auditors:
Purchase the TaiRx, Inc. report to view the information.
Incorporation Date:
August 22, 2011
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Senior Vice President
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
9.73%
Purchase this report to view the information.
0.67%
Purchase this report to view the information.
0.61%
Purchase this report to view the information.
0.55%
Purchase this report to view the information.
0.52%
Subsidiaries
Tairx Pharmaceuticals Co., Ltd. (Samoa)
100%
Tairx Us, Inc. (United States)
94.12%
Company Performance
Financial values in the chart are available after TaiRx, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
881.48%▲
Total operating revenue
881.48%▲
Operating profit (EBIT)
25.86%▲
EBITDA
26.11%▲
Net Profit (Loss) for the Period
28.42%▲
Total assets
78.38%▲
Total equity
86.53%▲
Operating Profit Margin (ROS)
348515.61%▲
Net Profit Margin
344607.26%▲
Return on Equity (ROE)
16.23%▲
Quick Ratio
11.82%▲
Cash Ratio
4.34%▲

Similar companies

Syngen Biotech Co., Ltd.
 
DV Biomed Co., Ltd.
CH Biotech R&D Co., Ltd.
 
Medigen Biotechnology Corporation
EirGenix Inc.
 
Glac Biotech Co., Ltd. (Tainan City) (丰华生物科技 (台南市))
Health Ever Bio-Tech Co., Ltd. (Taipei) (健永生技股份有限公司(台北市))
 
Bio Preventive Medicine Corp.
Senhwa Biosciences, Inc.
 
Great Novel Therapeutics Biotech & Medic
TWI Biotechnology, Inc.
 

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo